Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Alcoholism, Schizophrenia
About this trial
This is an interventional treatment trial for Alcoholism focused on measuring glycine, treatment, alcohol dependence, schizophrenia
Eligibility Criteria
Inclusion Criteria: DSM-IV diagnosis of schizophrenia or schizoaffective disorder DSM-IV diagnosis of alcohol dependence Stable treatment with typical or atypical antipsychotics Exclusion Criteria: Axis I diagnosis other than alcohol dependence, schizophrenia, schizoaffective disorder, OCD, and PTSD. current drug dependence evidence of significant hepatocellular injury evidence by abnormal SGOT or SGPT levels history of seizures diabetes and medical conditions that would alter glycine metabolism positive pregnancy test treatment with clozapine, naltrexone or disulfiram
Sites / Locations
- VA Connecticut Healthcare System
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Glycine
placebo
Glycine, 0.8 gr per kg given in two daily doses
placebo will be administered.